What does the future hold for Mast Therapeutics Inc (NYSEMKT:MSTX)? Roth Capital analyst Michael Higgins weighs in on the biotech company, providing investors a summary of the potential outcomes from Mast’s pivotal phase 3 “EPIC” study for the treatment of sickle cell crisis.

Outcome 1: “If vepoloxamer reduces the duration (and total dose) of IV opioids by 20+ hours in the overall population, as well as among children and those on HU, we would expect MSTX’s shares to more than double.”

Outcome 2: “At 30% probability, we view this as the most likely outcome, with reductions in IV opioid durations that are 16+ hours less than standard of care. We don’t expect the secondary outcomes will have to be met to be approved, but with 16+ hour reductions, we would expect to see improvements in the secondary outcomes.”

Outcome 3: “While less likely, it is possible vepoloxamer treatment produces a reduction in the duration of IV opioids for the entire patient set, but “misses” on either kids or HU patients. Another surprising outcome may include an unbalance on the secondary outcomes.”

Higgins reiterated a Buy rating on shares of Mast Therapeutics, with a price target of $2.00, which implies an upside of 355% from current levels

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Michael Higgins has a yearly average return of -15.2% and a 27.7% success rate. Higgins has a -14.5% average return when recommending MSTX, and is ranked #3861 out of 4060 analysts.

All the 5 analysts polled by TipRanks rate Mast Therapeutics stock a Buy. With a return potential of 526%, the stock’s consensus target price stands at $2.75.